Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Cyclolab and EpiPharma have signed an agreement to form a joint venture specialty pharmaceutical company to develop and commercialize novel conjugated Cyclodextrin – Peptide drug candidates for the treatment of debilitating CNS and Pulmonary diseases.
Lead Product(s): Conjugated cyclodextrin-peptide therapies
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Peptide
Recipient: EpiPharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 11, 2021